


What is claimed:

1. A compound of formula I



Formula I

wherein

---[b] is a single or double bond;

Each X, Y, and Z is independently selected from H, -OH, -O-alkyl, and -O-substituted alkyl;

R₁ is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;

R₂ is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;

R₃ is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and -A-E-R₈;

A is selected from alkyl and substituted alkyl;

E is selected from -N(R₁₀)C(O)-, -C(O)N(R₁₀)-, -N(R₁₀)C(S)-, -C(S)N(R₁₀)-, -S(O)N(R₁₀)-, -N(R₁₀)S(O)-, -S(O)₂N(R₁₀)-, and -N(R₁₀)S(O)₂-;

Each R₄, R₅, R₆, and R₇ is independently selected from H, halogen, aryl, -CN, -NO₂, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, -OR₉, -NH₂, -C(O)NH₂, -C(S)NH₂, and -S(O)_naryl, provided that one of R₄, R₅, R₆, and R₇ is -S(O)_naryl, and that at least one of R₄, R₅, R₆, and R₇ is H;


n is 0, 1, or 2;

Each R₈, R₉, and R₁₀ is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;

Each R_{11} is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, phenyl, naphthyl, and heteroaromatic, provided that any of the alkyl, cycloalkyl, phenyl, naphthyl, or heteroaromatic is optionally substituted with up to 3 substituents independently selected from halogen, alkyl, $-CF_3$, $-OR_{12}$, $-SR_{12}$, $-CN$, $-NO_2$, $-N_3$, $-N(R_{12})_2$, $-C(O)N(R_{12})_2$, and $-C(S)N(R_{12})_2$;

Each R_{12} is independently selected from H, alkyl, and cycloalkyl, provided that any of the alkyl or cycloalkyl is optionally substituted with up to 2 substituents independently selected from halogen, $-CF_3$, $-NO_2$, $-NH_2$, $-N_3$, $-CN$, $-OH$, $-O$ -lower alkyl, and $-O$ -lower substituted alkyl; and pharmaceutically acceptable salts thereof.

2. A compound of Claim 1 having the Formula Ib



Formula Ib

wherein

Each X, Y, and Z is independently selected from H, $-OH$, $-O$ -alkyl, and $-O$ -substituted alkyl;

R_1 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;

R_2 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;

R_3 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and $-A-E-R_8$;

A is selected from alkyl and substituted alkyl;

E is selected from $-N(R_{10})C(O)-$, $-C(O)N(R_{10})-$,

$-N(R_{10})C(S)-$, $-C(S)N(R_{10})-$, $-S(O)N(R_{10})-$, $-N(R_{10})S(O)-$, $-S(O)_2N(R_{10})-$, and $-N(R_{10})S(O)_2-$;

Each R_4 , R_5 , R_6 , and R_7 is independently selected from H, halogen, aryl, $-CN$, $-NO_2$, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, $-OR_9$, $-NH_2$, $-C(O)NH_2$, $-C(S)NH_2$, and $-S(O)_n\text{aryl}$, provided that one of R_4 , R_5 , R_6 , and R_7 is $-S(O)_n\text{aryl}$, and that at least one of R_4 , R_5 , R_6 , and R_7 is H;

n is 0, 1, or 2;

Each R_8 , R_9 , and R_{10} is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;

Each R_{11} is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, phenyl, naphthyl, and heteroaromatic, provided that any of the alkyl, cycloalkyl, phenyl, naphthyl, or heteroaromatic is optionally substituted with up to 3 substituents independently selected from halogen, alkyl, $-CF_3$, $-OR_{12}$, $-SR_{12}$, $-CN$, $-NO_2$, $-N_3$, $-N(R_{12})_2$, $-C(O)N(R_{12})_2$, and $-C(S)N(R_{12})_2$;

Each R_{12} is independently selected from H, alkyl, and cycloalkyl, provided that any of the alkyl or cycloalkyl is optionally substituted with up to 2 substituents independently selected from halogen, $-CF_3$, $-NO_2$, $-NH_2$, $-N_3$, $-CN$, $-OH$, $-O$ -lower alkyl, and $-O$ -lower substituted alkyl; and pharmaceutically acceptable salts thereof.

3. The compound of Claim 2, wherein one of R_1 and R_2 is H, and the other is H, alkyl, or substituted alkyl.

4. The compound of Claim 3, wherein R_5 is arylS(O)_n- , and wherein R_4 , R_6 , and R_7 are H.

5. The compound of Claim 4, wherein n is 2.
6. The compound of Claim 5, wherein R_3 is H or alkyl.
7. The compound of Claim 6, wherein the compound is
(rac)-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-amine;
(3*S*)-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-amine;
(3*R*)-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-amine;
(3*S*)-9-methyl-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-amine;
(3*R*)-9-methyl-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-amine;
(3*R*)-*N*,9-dimethyl-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-amine;
or a pharmaceutically acceptable salt thereof.
8. The compound of Claim 7, wherein the stereochemistry at the C-3 position is *R*.
9. The compound of Claim 8, wherein the compound is
(3*R*)-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-amine;
(3*R*)-9-methyl-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-amine;

(3R)-N,9-dimethyl-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine;

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound according to Claim 2.

11. A method for treating a disease or condition in a mammal in need thereof, wherein the 5-HT₆ receptor is implicated, comprising administering to the mammal a therapeutically effective amount of compound according to Claim 2.

12. The method according to Claim 11, wherein the disease or condition is anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, or epilepsy.

13. The method according to Claim 11, wherein said compound is administered rectally, topically, orally, sublingually, or parenterally.

14. The method according to Claim 11, wherein said compound is administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.

15. The method according to Claim 11, wherein said compound is administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.

16. The compound of Claim 2, wherein the compound includes at least one atom selected from Carbon-11, Nitrogen-13, Oxygen-15, and Fluorine-18.

17. A method of performing positron emission tomography comprising:

incorporating an isotopically labeled compound into tissue of a mammal, wherein the isotopically labeled compound is selected from a compound of Formula Ib as defined in Claim 1.

18. The method according to Claim 17, wherein the compound is selected from

6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1*H*-carbazol-3-amine;

(3*S*)-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1*H*-carbazol-3-amine;


(3*R*)-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1*H*-carbazol-3-amine;

(3*S*)-9-methyl-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1*H*-carbazol-3-amine;

(3*R*)-9-methyl-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1*H*-carbazol-3-amine; or

(3*R*)-*N*,9-dimethyl-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-amine.

19. A compound of Claim 1 having the Formula Ia



Formula Ia

wherein

Each X, Y, and Z is independently selected from H, -OH, -O-alkyl, and -O-substituted alkyl;

R₁ is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;

R₂ is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;

R₃ is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and -A-E-R₈;

A is selected from alkyl and substituted alkyl;

E is selected from -N(R₁₀)C(O)-, -C(O)N(R₁₀)-, -N(R₁₀)C(S)-, -C(S)N(R₁₀)-, -S(O)N(R₁₀)-, -N(R₁₀)S(O)-, -S(O)₂N(R₁₀)-, and -N(R₁₀)S(O)₂-;

Each R₄, R₅, R₆, and R₇ is independently selected from H, halogen, aryl, -CN, -NO₂, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, -OR₉, -NH₂, -C(O)NH₂, -C(S)NH₂, and -S(O)_naryl, provided that one of R₄, R₅, R₆, and R₇ is -S(O)_naryl, and that at least one of R₄, R₅, R₆, and R₇ is H;

n is 0, 1, or 2;

Each R₈, R₉, and R₁₀ is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;

Each R₁₁ is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, phenyl, naphthyl, and heteroaromatic, provided that any of the alkyl, cycloalkyl, phenyl, naphthyl, or heteroaromatic is optionally substituted with up to 3 substituents independently selected from halogen, alkyl, -CF₃, -OR₁₂, -SR₁₂, -CN, -NO₂, -N₃, -N(R₁₂)₂, -C(O)N(R₁₂)₂, and -C(S)N(R₁₂)₂;

Each R₁₂ is independently selected from H, alkyl, and

cycloalkyl, provided that any of the alkyl or cycloalkyl is optionally substituted with up to 2 substituents independently selected from halogen, -CF₃, -NO₂, -NH₂, -N₃, -CN, -OH, -O-lower alkyl, and -O-lower substituted alkyl; and pharmaceutically acceptable salts thereof.

20. The compound of Claim 19, wherein one of R₁ and R₂ is H, and the other is H, alkyl, or substituted alkyl.

21. The compound of Claim 20, wherein R₅ is arylS(O)_n-, and wherein R₄, R₆, and R₇ are H.

22. The compound of Claim 21, wherein n is 2.

23. The compound of Claim 22, wherein R₃ is H or alkyl.

24. The compound of Claim 23, wherein the compound is

(3R)-9-methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;

(3S)-9-methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;

(3R)-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;

(3S)-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;

(rac)-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol;

(3S)-N,9-dimethyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;

(3R)-N,9-dimethyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;
and pharmaceutically acceptable salts thereof.

25. The compound of Claim 23, wherein the stereochemistry at the C-3 position is R.

26. The compound of Claim 25, wherein the compound is
(3R)-9-methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;
or a pharmaceutically acceptable salt thereof.

27. A pharmaceutical composition comprising a compound according to Claim 19.

28. A method for treating a disease or condition in a mammal in need thereof, wherein the 5-HT₆ receptor is implicated, comprising administering to the mammal a therapeutically effective amount of compound according to Claim 19.

29. The method according to Claim 28, wherein the disease or condition is anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, or epilepsy.

30. The method according to Claim 28, wherein said compound is administered rectally, topically, orally, sublingually, or parenterally.

31. The method according to Claim 28, wherein said compound is administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.

32. The method according to Claim 28, wherein said compound is administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.

33. The compound of Claim 19, wherein the compound includes at least one atom selected from Carbon-11, Nitrogen-13, Oxygen-15, and Fluorine-18.

34. A method of performing positron emission tomography comprising:

incorporating an isotopically labeled compound into tissue of a mammal, wherein the isotopically labeled compound is selected from Claim 19.

35. The method according to Claim 34, wherein the compound is (3R)-9-methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine.